Skip to search formSkip to main contentSkip to account menu

AXL Inhibitor BGB324

Known as: BGB324 
An orally available and selective inhibitor of the AXL receptor tyrosine kinase (UFO), with potential antineoplastic activity. Upon administration… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label…
7043 Background: The RTK AXL represents a therapeutic target promoting AML cell proliferation and survival by pleiotropic… 
Review
2018
Review
2018
The Role of the TAM Family of Receptor Tyrosine Kinases in Neural Development and Disorders
Tyrosine kinase receptor 3 (Tyro3), Axl, and Mer constitute the TAM family of receptor tyrosine kinases. These receptor tyrosine… 
2018
2018
Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung.
TPS43Background: Activation of the receptor tyrosine kinase AXL has a profound suppressive effect on the innate immune system… 
2018
2018
A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic…
9548Background: Upregulation of the receptor tyrosine kinase Axl has been linked with both a reduced response to PD-1 blockade… 
2018
2018
Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.
3078Background: Bemcentinib (BGB324) is a first-in-class, oral, potent and highly selective inhibitor of the AXL tyrosine kinase… 
2018
2018
A randomized phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic…
Abstract Background Upregulation of the receptor tyrosine kinase Axl has been linked with both a reduced response to immune… 
2017
2017
Abstract 626: BGB324, a selective small molecule inhibitor of receptor tyrosine kinase AXL, abrogates tumor intrinsic and microenvironmental immune suppression and enhances immune checkpoint…
The AXL receptor tyrosine kinase is associated with poor overall survival in a wide spectrum of cancers including lung and breast… 
2016
2016
Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia
Axl is a receptor tyrosine kinase that has been shown to have a strong oncogenic potential in many cancer types. Overexpression… 
2015
2015
Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
Novel treatment options in acute myeloid leukemia (AML) are urgently needed; treatment has not changed significantly over the… 
2014
2014
BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant
BCR-ABL1 inhibitors have revolutionized the treatment of CML patients. However several drawbacks remain, including clinical… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)